Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Cash & Current Investments: 2018-2024

Historic Cash & Current Investments for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to $1.5 million.

  • Pharming Group N.V's Cash & Current Investments rose 30.17% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 28.83%. This contributed to the annual value of $1.5 million for FY2024, which is 1.51% down from last year.
  • As of FY2024, Pharming Group N.V's Cash & Current Investments stood at $1.5 million, which was down 1.51% from $1.5 million recorded in FY2023.
  • Pharming Group N.V's Cash & Current Investments' 5-year high stood at $206.2 million during FY2020, with a 5-year trough of $1.0 million in FY2021.
  • For the 3-year period, Pharming Group N.V's Cash & Current Investments averaged around $1.4 million, with its median value being $1.5 million (2024).
  • As far as peak fluctuations go, Pharming Group N.V's Cash & Current Investments skyrocketed by 168.11% in 2020, and later tumbled by 99.51% in 2021.
  • Pharming Group N.V's Cash & Current Investments (Yearly) stood at $206.2 million in 2020, then tumbled by 99.51% to $1.0 million in 2021, then grew by 8.55% to $1.1 million in 2022, then soared by 39.04% to $1.5 million in 2023, then dropped by 1.51% to $1.5 million in 2024.